Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study
Tolvaptan is well tolerated at low initial doses in Chinese patients with ADPKD. Significant improvements in eGFR and reduced HtTKV growth were observed in the overall population and across various baseline eGFR and final dose groups.
Authors
- Xiansen Wei
- Li Zhou (ORCID: https://orcid.org/0000-0002-9965-7533)
- Wenge Li (ORCID: https://orcid.org/0000-0002-4749-1009)
- Boya Wang (ORCID: https://orcid.org/0000-0002-2523-1898)
- Qianqian Xu (ORCID: https://orcid.org/0000-0003-2575-2068)
Institutions
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tau-24-448
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China-Japan Friendship Hospital